Skip to content

Study · Randomized controlled trial · n = 11 · 2019

11 results

Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide.

Øhrstrøm CC, Worm D, Højager A, Andersen D, Holst JJ, Kielgast UL, Hansen DL

Diabetes, obesity & metabolism24 Jun 2019Cited by 52 (Europe PMC)

PMID31144430 (opens in a new tab)DOI10.1111/dom.13796 (opens in a new tab)PepBankPUB-31144430
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with post-bariatric hypoglycaemia after Roux-en-Y gastric bypass, liraglutide had no effect on hypoglycaemia during the mixed-meal tolerance test.

    In plain wordsIn women with low blood sugar after gastric bypass surgery, liraglutide did not change low blood sugar during a test meal.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycaemia during mixed-meal tolerance test
    Study

    n = 11

    Comparator
    Baseline period without treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    verapamil and liraglutide had no effect on hypoglycaemia.
    2 context sentences
    Summary · context
    11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods with the following interventions: acarbose 50 mg for 1 week, sitagliptin 100 mg for 1 week, verapamil 120 mg for 1 wee…
    Summary · context
    Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with post-bariatric hypoglycaemia after Roux-en-Y gastric bypass, liraglutide had no impact on hypoglycaemia during continuous glucose monitoring.

    In plain wordsIn women with low blood sugar after gastric bypass surgery, liraglutide did not change low blood sugar measured over 6 days of monitoring.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycaemia during continuous glucose monitoring
    Study

    n = 11

    Comparator
    Baseline period without treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    During the CGM periods, the treatments had no impact on hypoglycaemia
    2 context sentences
    Summary · context
    11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods with the following interventions: acarbose 50 mg for 1 week, sitagliptin 100 mg for 1 week, verapamil 120 mg for 1 wee…
    Summary · context
    Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with post-bariatric hypoglycaemia after Roux-en-Y gastric bypass, liraglutide reduced hyperglycaemia during continuous glucose monitoring.

    In plain wordsIn women with low blood sugar after gastric bypass surgery, liraglutide lowered high blood sugar measured over 6 days of monitoring.

    Peptide
    Liraglutide
    Outcome
    DecreaseHyperglycaemia during continuous glucose monitoring
    Study

    n = 11

    Comparator
    Baseline period without treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    acarbose and liraglutide reduced hyperglycaemia and glycaemic variability.
    2 context sentences
    Summary · context
    11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods with the following interventions: acarbose 50 mg for 1 week, sitagliptin 100 mg for 1 week, verapamil 120 mg for 1 wee…
    Summary · context
    Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with post-bariatric hypoglycaemia after Roux-en-Y gastric bypass, liraglutide reduced glycaemic variability during continuous glucose monitoring.

    In plain wordsIn women with low blood sugar after gastric bypass surgery, liraglutide made blood sugar swing less over 6 days of monitoring.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlycaemic variability during continuous glucose monitoring
    Study

    n = 11

    Comparator
    Baseline period without treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    acarbose and liraglutide reduced hyperglycaemia and glycaemic variability.
    2 context sentences
    Summary · context
    11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods with the following interventions: acarbose 50 mg for 1 week, sitagliptin 100 mg for 1 week, verapamil 120 mg for 1 wee…
    Summary · context
    Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with post-bariatric hypoglycaemia, pasireotide significantly increased nadir glucose during meal testing versus untreated baseline.

    In plain wordsIn women with post-bariatric hypoglycaemia, pasireotide increased the lowest glucose level during meal testing compared with untreated baseline.

    Peptide
    Pasireotide
    Outcome
    IncreaseNadir glucose during mixed-meal tolerance test
    Study

    n = 11

    Comparator
    Baseline without treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    300 μg · single doseAs given in this study (human).

    Measurements

    Nadir glucose
    7.9 not stated
    pasireotide mean
    SEM
    0.4 not stated
    pasireotide
    Nadir glucose
    3.4 not stated
    untreated baseline mean
    SEM
    0.2 not stated
    untreated baseline
    P
    < 0.03
    comparison with baseline

    Source sentences

    Summary
    Treatment with acarbose and treatment with pasireotide both significantly lifted nadir glucose levels (mean ± SEM 3.9 ± 0.2 and 7.9 ± 0.4 vs 3.4 ± 0.2; P < .03) and reduced time in hypoglycaemia during the MMTTs.
    3 context sentences
    Summary · context
    In a randomized crossover study, 11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods
    Summary · context
    pasireotide 300 μg as a single dose.
    Summary · context
    Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).
  6. 06HumanNon-randomized trialEfficacy outcome

    In women with post-bariatric hypoglycaemia, pasireotide reduced time in hypoglycaemia during meal testing versus untreated baseline.

    In plain wordsIn women with post-bariatric hypoglycaemia, pasireotide reduced time with low glucose during meal testing compared with untreated baseline.

    Peptide
    Pasireotide
    Outcome
    DecreaseTime in hypoglycaemia during mixed-meal tolerance test
    Study

    n = 11

    Comparator
    Baseline without treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    300 μg · single doseAs given in this study (human).

    Source sentences

    Summary
    Treatment with acarbose and treatment with pasireotide both significantly lifted nadir glucose levels (mean ± SEM 3.9 ± 0.2 and 7.9 ± 0.4 vs 3.4 ± 0.2; P < .03) and reduced time in hypoglycaemia during the MMTTs.
    3 context sentences
    Summary · context
    In a randomized crossover study, 11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods
    Summary · context
    pasireotide 300 μg as a single dose.
    Summary · context
    Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with post-bariatric hypoglycaemia, pasireotide greatly increased peak glucose during meal testing versus untreated baseline.

    In plain wordsIn women with post-bariatric hypoglycaemia, pasireotide increased peak glucose during meal testing compared with untreated baseline.

    Peptide
    Pasireotide
    Outcome
    IncreasePeak glucose during mixed-meal tolerance test
    Study

    n = 11

    Comparator
    Baseline without treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    300 μg · single doseAs given in this study (human).

    Source sentences

    Summary
    Acarbose reduced peak glucose levels and time in hyperglycaemia, whereas pasireotide greatly increased both variables.
    3 context sentences
    Summary · context
    In a randomized crossover study, 11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods
    Summary · context
    pasireotide 300 μg as a single dose.
    Summary · context
    Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).
  8. 08HumanNon-randomized trialEfficacy outcome

    In women with post-bariatric hypoglycaemia, pasireotide greatly increased time in hyperglycaemia during meal testing versus untreated baseline.

    In plain wordsIn women with post-bariatric hypoglycaemia, pasireotide increased time with high glucose during meal testing compared with untreated baseline.

    Peptide
    Pasireotide
    Outcome
    IncreaseTime in hyperglycaemia during mixed-meal tolerance test
    Study

    n = 11

    Comparator
    Baseline without treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    300 μg · single doseAs given in this study (human).

    Source sentences

    Summary
    Acarbose reduced peak glucose levels and time in hyperglycaemia, whereas pasireotide greatly increased both variables.
    3 context sentences
    Summary · context
    In a randomized crossover study, 11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods
    Summary · context
    pasireotide 300 μg as a single dose.
    Summary · context
    Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).
  9. 09HumanNon-randomized trialEfficacy outcome

    In women with post-bariatric hypoglycaemia, pasireotide reduced insulin levels versus untreated baseline.

    In plain wordsIn women with post-bariatric hypoglycaemia, pasireotide reduced insulin levels compared with untreated baseline.

    Peptide
    Pasireotide
    Outcome
    DecreaseInsulin levels
    Study

    n = 11

    Comparator
    Baseline without treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    300 μg · single doseAs given in this study (human).

    Source sentences

    Summary
    Acarbose and pasireotide reduced insulin and C-peptide levels, and pasireotide also diminished glucagon-like peptide-1 levels.
    3 context sentences
    Summary · context
    In a randomized crossover study, 11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods
    Summary · context
    pasireotide 300 μg as a single dose.
    Summary · context
    Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).
  10. 10HumanNon-randomized trialEfficacy outcome

    In women with post-bariatric hypoglycaemia, pasireotide reduced C-peptide levels versus untreated baseline.

    In plain wordsIn women with post-bariatric hypoglycaemia, pasireotide reduced C-peptide levels compared with untreated baseline.

    Peptide
    Pasireotide
    Outcome
    DecreaseC-peptide levels
    Study

    n = 11

    Comparator
    Baseline without treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    300 μg · single doseAs given in this study (human).

    Source sentences

    Summary
    Acarbose and pasireotide reduced insulin and C-peptide levels, and pasireotide also diminished glucagon-like peptide-1 levels.
    3 context sentences
    Summary · context
    In a randomized crossover study, 11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods
    Summary · context
    pasireotide 300 μg as a single dose.
    Summary · context
    Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).
  11. 11HumanNon-randomized trialEfficacy outcome

    In women with post-bariatric hypoglycaemia, pasireotide diminished glucagon-like peptide-1 levels versus untreated baseline.

    In plain wordsIn women with post-bariatric hypoglycaemia, pasireotide reduced glucagon-like peptide-1 levels compared with untreated baseline.

    Peptide
    Pasireotide
    Outcome
    DecreaseGlucagon-like peptide-1 levels
    Study

    n = 11

    Comparator
    Baseline without treatment
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    300 μg · single doseAs given in this study (human).

    Source sentences

    Summary
    Acarbose and pasireotide reduced insulin and C-peptide levels, and pasireotide also diminished glucagon-like peptide-1 levels.
    3 context sentences
    Summary · context
    In a randomized crossover study, 11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods
    Summary · context
    pasireotide 300 μg as a single dose.
    Summary · context
    Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 3

    27 Oct 2026, 16:34 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.